FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to polypeptides that bind to the programmed death ligand 1 (PD-L1), and can be used in medicine.
EFFECT: resulting PD-L1-binding polypeptides containing the following sequence - ERNX4AAX7EILX11LPNLX16X17X18QX20WAFIWX26LX28D, can be effectively used as a diagnostic or therapeutic agent for PD-L1-associated disorder.
35 cl, 12 dwg, 19 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES AGAINST LIGAND-1 PROGRAMMED DEATH (PD-L1) AND APPLICATION THEREOF | 2017 |
|
RU2721582C1 |
| ANTIBODIES AGAINST PD-L1 AND THEIR OPTIONS | 2017 |
|
RU2770590C2 |
| FUSED PROTEINS WITH ALBUMIN-BINDING DOMAINS | 2018 |
|
RU2786444C2 |
| PROGRAMMED CELL DEATH (PD-1) PROTEIN-1 ANTIBODIES AND USE THEREOF | 2017 |
|
RU2725950C1 |
| IL-17A-BINDING POLYPEPTIDES | 2016 |
|
RU2749712C2 |
| HYBRID PROTEINS OF sPD-1-Fc VARIANT | 2019 |
|
RU2785993C2 |
| POLYPEPTIDES RECRUITING T-CELLS, CAPABLE OF BINDING CD123 AND ALPHA/BETA TCR | 2017 |
|
RU2775063C2 |
| NEONATAL Fc RECEPTOR BINDING AFFIMERS | 2020 |
|
RU2817008C1 |
| POLYPEPTIDE COMPRISING ANTIGEN-BINDING DOMAIN AND TRANSPORT SEGMENT | 2018 |
|
RU2815452C2 |
| COMBINATIONS OF ANTIBODIES FOR TREATING CANCER IN SPECIFIC PATIENTS | 2020 |
|
RU2816531C2 |
